We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

ORAL ANTICOAGULANT THERAPY IN CLINICAL PRACTICE: THE MULTICENTER RESTAIC REGISTRY.

Submitted

13 Views
0 Downloads
0 Saves

Presented at

ESOC-2019

-

Presentation

thumbnail

Abstract

Background and Aims: After the development of the novel oral anticoagulants (NOAC) for stroke prevention, prospective registries to evaluate the results of their implementation in clinical practice are mainly based on primary prevention. Our aim is to explore the long-term outcomes differences according to the oral anticoagulation (OAC) in secondary stroke prevention. Methods: A prospective, multicentric, registry including IS patients who were discharged under OAC. Three months follow-up was scheduled at outpatient clinic with subsequent annual phone interviews for 3 years. Principal outcomes: stroke recurrences, intracranial hemorrhage, mayor hemorrhage and mortality. Patients were classified and compared into 4 study groups according to OAC at discharge: Vitamin K antagonist (AVK), Factor Xa inhibitor (FXa-I), direct thrombin inhibitor (DTI) and non-OAC. Results: 256 patients were included. Patients under FXa-I were older (age >75: 47.9% vs. 22.2% AVK, 14.5% DTI and 15.4% other OAC P=.001), had higher frequency of hypertension (40% vs. 29% AVK, 15% DTI and 14 % other OAC P=.006), had higher CHA2DS2-VASc (median 6 vs. 5 in all the other groups; P=.001) and HASBLED scores (median 3 vs. 2 in the other groups; P=.02). We found low mortality rates (3 death/year), stroke recurrences (5.6 stroke/year), intracranial hemorrhages (0.6 hemorrhage/year) and major hemorrhages (0.6 hemorrhage/year) for the first year, without differences according to the type of OAC. For the second and third year, no intracranial hemorrhages were reported and the incidence rate decline to 0.05 stroke/year. Conclusions: Stroke secondary prevention with OAC is safe without significant differences in stroke recurrence rates at long-term between anticoagulant treatments.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Morressier

Company

Legal

Follow us

© Copyright 2020 Morressier GmbH. All rights reserved.

Morressier

© Copyright 2020 Morressier GmbH.
All rights reserved.